MedTrace Logo

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

NCT03750071 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-20

No results posted yet for this study

Summary

VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery

Conditions

Interventions

BIOLOGICAL

VXM01

Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid

BIOLOGICAL

Avelumab

Monoclonal anti-PD-L1 Antibody

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Vaximm GmbH

    lead INDUSTRY

Principal Investigators

  • Wolfgang Wick, MD · University Clinics Heidelberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03750071 on ClinicalTrials.gov